Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen
- Sprache
-
Englisch
- Identifier
-
1241672865
- Thema
-
Spinale Muskelatrophie; Multiple Sklerose
- Beteiligte Personen und Organisationen
-
Koch, Jan C.
Cordts, Isabell
Dreyhaupt, Jens
Otto, Markus
Uzelac, Zeljko
Witzel, Simon
Winter, Benedikt
Kocak, Tugrul
Schocke, Michael
Weydt, Patrick
Wollinsky, Kurt
Ludolph, Albert C.
Deschauer, Marcus
Lingor, Paul
Tumani, Hayrettin
Hermann, Andreas
Günther, René
Wurster, Claudia Diana
- DOI
-
10.18725/OPARU-38822
- URN
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
26.01.2023, 13:53 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Koch, Jan C.
- Cordts, Isabell
- Dreyhaupt, Jens
- Otto, Markus
- Uzelac, Zeljko
- Witzel, Simon
- Winter, Benedikt
- Kocak, Tugrul
- Schocke, Michael
- Weydt, Patrick
- Wollinsky, Kurt
- Ludolph, Albert C.
- Deschauer, Marcus
- Lingor, Paul
- Tumani, Hayrettin
- Hermann, Andreas
- Günther, René
- Wurster, Claudia Diana
Ähnliche Objekte (12)
Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy
Diagnosis and management of spinal muscular atrophy : : Part 2
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
Costs of illness of spinal muscular atrophy: a systematic review
Defective Mitochondria Contribute to Impaired Translation in Spinal Muscular Atrophy
Cytoskeletal dysregulation in the motoneuron disease Spinal Muscular Atrophy (SMA)
Molecular mechanisms of cytoskeletal dysregulations in Spinal Muscular Atrophy (SMA)
J wave syndromes in patients with spinal and bulbar muscular atrophy
Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes
Development of antisense oligonucleotide combinatorial therapies for spinal muscular atrophy (SMA)
Novel modifiers for inherited neurodegenerative disorders : spinal muscular atrophy and ataxia
Combination disease‐modifying treatment in spinal muscular atrophy: a proposed classification
Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy
Diagnosis and management of spinal muscular atrophy : : Part 2
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
Costs of illness of spinal muscular atrophy: a systematic review
Defective Mitochondria Contribute to Impaired Translation in Spinal Muscular Atrophy
Cytoskeletal dysregulation in the motoneuron disease Spinal Muscular Atrophy (SMA)
Molecular mechanisms of cytoskeletal dysregulations in Spinal Muscular Atrophy (SMA)
J wave syndromes in patients with spinal and bulbar muscular atrophy
Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes
Development of antisense oligonucleotide combinatorial therapies for spinal muscular atrophy (SMA)
Novel modifiers for inherited neurodegenerative disorders : spinal muscular atrophy and ataxia
Combination disease‐modifying treatment in spinal muscular atrophy: a proposed classification
Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy
Diagnosis and management of spinal muscular atrophy : : Part 2
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
Costs of illness of spinal muscular atrophy: a systematic review
Defective Mitochondria Contribute to Impaired Translation in Spinal Muscular Atrophy
Cytoskeletal dysregulation in the motoneuron disease Spinal Muscular Atrophy (SMA)
Molecular mechanisms of cytoskeletal dysregulations in Spinal Muscular Atrophy (SMA)
J wave syndromes in patients with spinal and bulbar muscular atrophy
Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes
Development of antisense oligonucleotide combinatorial therapies for spinal muscular atrophy (SMA)
Novel modifiers for inherited neurodegenerative disorders : spinal muscular atrophy and ataxia